Each archive includes the full-color, searchable, PDF files of articles and formulations from the Journal.

CD Prices
1 = $95
2 to 5 = $85 each
6 to 9 = $75 each
10 + = $65 each

Library CD
Volume 21, 2017 CD
Six back issues from 2017 on one convenient CD.
Permanent storage and easy retrieval of IJPC articles and formulations.
Only $95 per CD
  • Print journal articles in color from the PDF file for your marketing needs.
  • Eliminate long searches through past issues for formulations, compatibility studies, standard operating procedures, marketing ideas, and literature reviews.

This CD contains the following articles listed by volume, issue and page number:

Issues Included
Volume/Issue Date Title
Vol. 21 No. 1 January/February 2017 Volume 21, Number 1
Vol. 21 No. 2 March/April 2017 Volume 21, Number 2
Vol. 21 No. 3 May/June 2017 Volume 21, Number 3
Vol. 21 No. 4 July/August 2017 Volume 21, Number 4
Vol. 21 No. 5 September/October 2017 Volume 21, Number 5
Vol. 21 No. 6 November/December 2017 Volume 21, Number 6

Volume 21, 2017 CD ARTICLES

Volume 21, 2017 CD ARTICLES
Title (Click for Details) Vol/Issue Page
PreScription: Compounding Pharmacy Issues for 2017 Vol. 21 No. 1 4
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 3 Vol. 21 No. 1 6
When to Compound Medications for Veterinary Patients Vol. 21 No. 1 19
Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications Vol. 21 No. 1 22
Why You Should Become an International Academy of Compounding Pharmacists Member Vol. 21 No. 1 28
Analytic Methods Used in Quality Control in a Compounding Pharmacy Vol. 21 No. 1 31
Basics of Compounding with Dilutions and Concentrates Vol. 21 No. 1 39
Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms Vol. 21 No. 1 47
Calculations Vol. 21 No. 1 58
Clindamycin 10-mg/mL Oral Suspension Vol. 21 No. 1 60
Diazoxide 10-mg/mL Oral Suspension Vol. 21 No. 1 61
Infliximab 1% Ophthalmic Solution Vol. 21 No. 1 62
Nifedipine 0.5% Rectal Ointment Vol. 21 No. 1 63
Tetracaine Hydrochloride 0.5% Ophthalmic Solution Vol. 21 No. 1 64
Zonisamide 10-mg/mL Oral Suspension Vol. 21 No. 1 65
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Vol. 21 No. 1 66
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Vol. 21 No. 1 76
A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding Vol. 21 No. 1 83
PreScription: Whatever Happened to Common Sense? Vol. 21 No. 2 92
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Vol. 21 No. 2 95
Restructuring the Art of Health by Pharmacists: Formulation Designs with Oral Vehicles--Teaching Pharmacy Students Vol. 21 No. 2 105
Consultation for Human, Veterinary, and Compounded Medications Vol. 21 No. 2 111
The International Academy of Compounding Pharmacists Introduces a New President Vol. 21 No. 2 116
Quality Control: (Material) Safety Data Sheets Vol. 21 No. 2 118
Basics of Compounding: 3D Printing--Pharmacy Applications, Part 1 Vol. 21 No. 2 127
Accuracy Considerations in Sterile Compounding Vol. 21 No. 2 133
Calculations Vol. 21 No. 2 144
Azathioprine 10-mg/mL Oral Suspension Vol. 21 No. 2 146
Candesartan Cilexetil 8 mg Liquid-Filled Capsules Vol. 21 No. 2 147
Furosemide 10-mg/mL Oral Suspension Vol. 21 No. 2 148
Ketoconazole 20-mg/mL Oral Suspension Vol. 21 No. 2 149
Stability of Alprostadil in 0.9% Sodium Chloride Stored in Polyvinyl Chloride Containers Vol. 21 No. 2 150
Stability of Two Antifungal Agents, Fluconazole and Miconazole, Compounded in HUMCO RECURA Topical Cream to Determine Beyond-Use Date Vol. 21 No. 2 154
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions Vol. 21 No. 2 160
Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs Vol. 21 No. 2 164
Suspensions as a Valuable Alternative to Extemporaneously Compounded Capsules Vol. 21 No. 2 171
PreScription: United States Pharmacopeia Chapter <800> Comments and Alternatives Vol. 21 No. 3 180
Adventures in the Environmental World and Environmental Microbiology Sampling of Air for Pharmaceutical Sterile Compounding Vol. 21 No. 3 182
Microbiologic Testing for 503A Sterile-Compounding Pharmacies Vol. 21 No. 3 193
Management of Psoriasis with a XemaTop Topical Compounded Formula: A Case Report Vol. 21 No. 3 205
International Academy of Compounding Pharmacists Legislative/Regulatory Update Vol. 21 No. 3 212
Basics of Compounding: 3D Printing--Pharmacy Applications, Part 2 Vol. 21 No. 3 215
Basics of Sterile Compounding: Manipulating Peptides and Proteins Vol. 21 No. 3 223
Calculations Vol. 21 No. 3 230
Candesartan Cilexetil 0.1-mg/mL to 2.0-mg/mL Oral Suspension Vol. 21 No. 3 232
Ketoconazole 20-mg/mL in SyrSpend SF pH4 Oral Suspension Vol. 21 No. 3 233
Ketoprofen 10%, Baclofen 2%, Cyclobenzaprine Hydrochloride 2%, Lidocaine 2% in Lipopen Ultra Cream Base Vol. 21 No. 3 234
Meloxicam 1% Topical Gel Vol. 21 No. 3 235
Ofloxacin 0.3% Ophthalmic Solution Vol. 21 No. 3 236
PVP Iodine 10% Antiseptic Cream Vol. 21 No. 3 237
Tri-Est, Progesterone, and Testosterone in Versatile, Phytobase, Fitaline, and HRT Supreme Cream Bases Vol. 21 No. 3 238
Trimethoprim 10-mg/mL Oral Suspension Vol. 21 No. 3 239
Updated Stability Data for Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSpend SF and Minoxidil in Espumil Vol. 21 No. 3 240
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Vol. 21 No. 3 242
Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance Vol. 21 No. 3 247
Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes Vol. 21 No. 3 251
Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions Vol. 21 No. 3 255
PreScription: Just Think About It! Vol. 21 No. 4 268
Change Is In the Air: What You Need to Know About Pharmacy Ventilation Under United States Pharmacopeia <800> Vol. 21 No. 4 271
Component Selection for Sterile Compounding Vol. 21 No. 4 277
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas Vol. 21 No. 4 282
The International Academy of Compounding Pharmacists Applauds the Leadership of Congressmen Griffith and Cuellar in Introducing Bill HR 2871 Vol. 21 No. 4 290
Basics of Compounding: 3D Printing: Pharmacy Applications, Part 3: Compounding, Formulation Considerations, and the Future Vol. 21 No. 4 293
Basics of Sterile Compounding: Excipients Used in Injections Vol. 21 No. 4 301
Calculations Vol. 21 No. 4 310
Betamethasone 0.1% and Neomycin 0.6% Gel-Cream Vol. 21 No. 4 312
Castor Oil 50% in Modified Pluronic Lecithin Organogel Gel Vol. 21 No. 4 313
Copper Sulfate, Magnesium Sulfate, Phenylephrine, and Guaifenesin Pluronic Lecithin Organogel Vol. 21 No. 4 314
Disopyramide 100-mg Capsules Vol. 21 No. 4 315
Ferrous Sulfate 30-mg Fe/mL Oral Drops Vol. 21 No. 4 316
Reteplase Injection Vol. 21 No. 4 317
Sertraline Hydrochloride 10-mg/mL Oral Suspension Vol. 21 No. 4 318
Tacrolimus 0.06% Ophthalmic Drops Vol. 21 No. 4 319
Torsemide 10-mg/mL Injection Vol. 21 No. 4 320
Tranilast 8% Pluronic Lecithin Organogel Gel Vol. 21 No. 4 321
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Vol. 21 No. 4 322
Compounded Levofloxacin Triple Therapy is Safe and Effective for Refractory Helicobacter pylori Vol. 21 No. 4 330
Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt Vol. 21 No. 4 334
Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Vol. 21 No. 4 339
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia Vol. 21 No. 4 347
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Vol. 21 No. 5 356
Compounding Opportunities in Urology Vol. 21 No. 5 358
Child-safety Containers/Devices and Compounding Vol. 21 No. 5 364
Documentation: Records and Reports Vol. 21 No. 5 373
IACP Legislative/Regulatory Update Vol. 21 No. 5 382
Quality Control: Bar Codes and Bar Code Scanners for Unit-Dose Medications in a Healthcare Setting Vol. 21 No. 5 384
Basics of Compounding: 3D Printing--Pharmacy Applications: Geometric Shape Effects on 3D Printing Vol. 21 No. 5 388
Basics of Sterile Compounding: Particulate Matter Vol. 21 No. 5 395
Calculations Vol. 21 No. 5 406
Acetylcysteine Solutions for Inhalation Vol. 21 No. 5 408
Carbamazepine 25-mg/mL in SyrSPend SF pH4 Oral Suspension Vol. 21 No. 5 409
Etoposide 20-mg/mL Injection Vol. 21 No. 5 410
Fentanyl Citrate 50-mcg/mL Injection Vol. 21 No. 5 411
Fluoxymesterone 10-mg Capsules Vol. 21 No. 5 412
Ioversol Injection Vol. 21 No. 5 413
Levocarnitine 100-mg/mL Oral Solution Vol. 21 No. 5 414
Peritoneal Dialysis Solution with 1.5%, 2.5%, or 4.25% Dextrose Vol. 21 No. 5 415
Tacrolimus 0.3-mg/mL Ophthalmic Solution Vol. 21 No. 5 416
Vancomycin 50 mg/mL in Oral Syrup Suspension Vol. 21 No. 5 417
Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3) Vol. 21 No. 5 418
Stability of Dalteparin 1,000 Unit/mL in 0.9% Sodium Chloride for Injection in Polypropylene Syringes Vol. 21 No. 5 426
Physicochemical Stability of an Oral Suspension of Trimethoprim 20 mg/mL in Combination with Sulfadiazine 200 mg/mL in PCCA Base SuspendIt Vol. 21 No. 5 430
Stability of Dexmedetomidine in 0.9% Sodium Chloride in Two Types of Intravenous Infusion Bags Vol. 21 No. 5 436
PreScription: Issues with the NAMS 2017 Hormone Therapy Position Statement Vol. 21 No. 6 444
Feline Transdermal Formulation Considerations Vol. 21 No. 6 446
Orodispersible Films for Compounding Pharmacies Vol. 21 No. 6 454
Features of Pharmaceutical Compounding in the Republic of Tajikistan Vol. 21 No. 6 463
Join the Partnership for Personalized Prescriptions (P3) Advocacy Effort! Vol. 21 No. 6 468
Basics of Compounding: Hot Melt Extrusion Vol. 21 No. 6 471
Basics of Compounding: Compounding Irrigation Solutions for Sterile and Nonsterile Preparations Vol. 21 No. 6 481
Calculations Vol. 21 No. 6 488
Amitriptyline 20 mg/mL in OraPlus:OraSweet Suspension Vol. 21 No. 6 490
Dapsone 2 mg/mL in SyrSpend SF pH4 Oral Suspension Vol. 21 No. 6 491
Fluconazole 10% in RECURA Cream Vol. 21 No. 6 492
Haloperidol 5-mg/mL Injection Vol. 21 No. 6 493
Hydroxychloroquine Sulfate 25 mg/mL in Oral Mix or Oral Mix SF Vol. 21 No. 6 494
Promethazine Hydrochloride 12.5 mg/0.1 mL in PLO Gel Vol. 21 No. 6 495
Spironolactone 5 mg/mL in SuspendIt Oral Suspension Vol. 21 No. 6 496
Tolmetin 400-mg Capsules Vol. 21 No. 6 497
Trace Elements Injection 5 Vol. 21 No. 6 498
Vancomycin 5-mg/mL Injection Vol. 21 No. 6 499
To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid Vol. 21 No. 6 500
Validation of the Technological Process of the Preparation "Milk by Vidal" Vol. 21 No. 6 513
Auditing Safety of Compounding and Reconstituting of Intravenous Medicines on Hospital Wards in Finland Vol. 21 No. 6 518
Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives Vol. 21 No. 6 530